Efficacy of intermittent short-term use of a real-time continuous glucose monitoring system in non-insulin–treated patients with type 2 diabetes: A randomized controlled trial
- Authors
- Moon, S.J.[Moon, S.J.]; Kim, K.-S.[Kim, K.-S.]; Lee, W.J.[Lee, W.J.]; Lee, M.Y.[Lee, M.Y.]; Vigersky, R.[Vigersky, R.]; Park, C.-Y.[Park, C.-Y.]
- Issue Date
- Jan-2023
- Publisher
- John Wiley and Sons Inc
- Keywords
- continuous glucose monitor; glycaemic control; self-monitoring of blood glucose; type 2 diabetes
- Citation
- Diabetes, Obesity and Metabolism, v.25, no.1, pp.110 - 120
- Indexed
- SCOPUS
- Journal Title
- Diabetes, Obesity and Metabolism
- Volume
- 25
- Number
- 1
- Start Page
- 110
- End Page
- 120
- URI
- https://scholarworks.bwise.kr/skku/handle/2021.sw.skku/100708
- DOI
- 10.1111/dom.14852
- ISSN
- 1462-8902
- Abstract
- Aim: To evaluate the efficacy of intermittent short-term use of a real-time continuous glucose monitoring (RT-CGM) system in non-insulin–treated patients with type 2 diabetes (T2D) uncontrolled with oral antidiabetic drugs (OADs). Materials and Methods: In this multicentre, randomized prospective study, 61 participants were randomly assigned to treatment group 1 (one session of RT-CGM), treatment group 2 (two sessions of RT-CGM with a 3-month interval between sessions) and a control group. All participants used blinded continuous glucose monitoring for up to 6 days with education before randomization, and RT-CGM was additionally applied for 1 week in the intervention groups. The primary outcome was change in HbA1c at 6 months. Results: Among 61 participants, 48 subjects completed the study (baseline HbA1c 8.2% ± 0.5%). At 3 months, a significant HbA1c reduction was observed in treatment group 1 (adjusted difference = −0.60%, P =.044) and treatment group 2 (adjusted difference = −0.64%, P =.014) compared with the control group. However, at 6 months, only treatment group 2 achieved a significant HbA1c reduction (adjusted difference = −0.68%, P =.018). Especially in the treatment groups, patients performing self-monitoring of blood glucose (SMBG) at least 1.5 times/day showed a significant HbA1c improvement, at both 3 and 6 months, but those performing SMBG less than 1.5 times/day showed no significant improvement. Conclusions: In non-insulin–treated patients with T2D uncontrolled with OADs, intermittent short-term use of RT-CGM was an effective method for glucose control, especially in those performing SMBG frequently. © 2022 John Wiley & Sons Ltd.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - Medicine > Department of Medicine > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/skku/handle/2021.sw.skku/100708)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.